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The Journal of Immunology
Chemical Chaperones Curcumin and 4-Phenylbutyric Acid
Improve Secretion of Mutant Factor H R127H by Fibroblasts
from a Factor H-Deficient Patient
Jose´ Antonio T. Albuquerque,* Marcelo L. Lamers,† Mo´nica M. Castiblanco-Valencia,*
Marinilce dos Santos,‡ and Lourdes Isaac*
Factor H (FH) is one of the most important regulatory proteins of the alternative pathway of the complement system. Patients with
FH deficiency have a higher risk for development of infections and kidney diseases because of the uncontrolled activation and
subsequent depletion of the central regulatory component C3 of the complement system. In this study, we investigated the con-
sequences of the Arg127His mutation in FH (FHR127H) previously described in an FH-deficient patient, on the secretion of this
protein by skin fibroblasts in vitro. We observed that, although the patient cells stimulated with IFN-g were able to synthesize
FHR127H, the mutant protein was largely retained within the endoplasmic reticulum (ER), whereas normal human fibroblasts
stimulated with IFN-g secrete FH without retention in the ER. Moreover, the retention of FHR127H provoked enlargement of ER
cisterns after treatment with IFN-g. A similar ER retention was observed in Cos-7 cells expressing the mutant FHR127H protein.
Despite this deficiency in secretion, we show that the FHR127H mutant is capable of functioning as a cofactor in the Factor
I-mediated cleavage of C3. We then evaluated whether a treatment could increase the secretion of FH, and observed that the
patient’s fibroblasts treated with the chemical chaperones 4-phenylbutiric acid or curcumin increased the secretion rate of FH. We
propose that these chemical chaperones could be used as alternative therapeutic agents to increase FH plasma levels in FH-
deficient patients caused by secretion delay of this regulatory protein. The Journal of Immunology, 2012, 189: 3242–3248.
T
he complement system is one of the first defense barriers
against microorganisms. This system consists of .30
soluble and cell-bound proteins, and can be activated by
the classic, alternative, and lectin pathways (1, 2). As a result of
this activation, a cascade of biochemical events is triggered with
important biological consequences such as inflammation, lysis of
pathogens and altered cells, clearance of immune complexes and
apoptotic cells, opsonization of foreign particles for enhanced
phagocytosis, binding to specific receptors on immune cell surfa-
ces inducing cellular activation, and secretion of regulatory mol-
ecules that act in the innate and acquired immune responses (2).
The constitutive activation of the alternative pathway is re-
sponsible for most of the complement activities in the serum. This
pathway is activated spontaneously after hydrolysis of a thio-ester
bond located in the C3 a-chain, generating C3(H2O), which
presents a binding site for Factor B (FB). Once FB is complexed
to C3(H2O), Factor D cleaves FB, releasing the fragment Ba. The
complex C3(H2O)Bb is the first C3-convertase of the alternative
pathway and cleaves C3, generating C3a and C3b fragments. C3b
can complex to FB to form C3bB, which is cleaved by Factor D
to generate C3bBb, the second C3-convertase of the alternative
pathway. As more C3b fragments are formed, the activation of the
alternative pathway is amplified (3). To prevent exacerbated ac-
tivation, which leads to complement-mediated tissue damage and
wasteful consumption of complement components, the alternative
pathway must be tightly regulated. One of the most important
regulatory proteins is Factor H (FH). This 150-kDa protein is
mainly synthesized by the liver and consists of 20 globular short
consensus repeat (SCR) domains (4). FH has multiple binding
regions for C3b that are located within SCRs 1–4, 12–15, and 19–
20, and for heparin, located in SCR7, 9, 12–14, and 19–20 (5).
Moreover, the C-terminal domain of FH contains regions for in-
teraction with both C3b and C3d fragments with heparin and
glycosaminoglycan molecules, whereas the N-terminal region
(SCRs 1–4) of the molecule is responsible for complement regu-
latory activity (5) because it binds preferably to C3b fragments.
FH regulates the alternative pathway by competing with FB for
C3b binding, preventing the formation of the alternative pathway
C3-convertase and attenuating C3 consumption on self-cells.
Moreover, FH is an important cofactor of Factor I (FI), and its
ability to cleave C3b and generate iC3b on the surface of pathogens
(2). The modulation of these functions requires the recognition of
cell membrane components such as sialic acid and polyanions (6, 7).
Patients with FH deficiency are more susceptible to recurrent
infections as a consequence of diminished C3 levels because of its
uncontrolled consumption. They are also prone to develop mem-
branoproliferative glomerulonephritis type II (MPGN II) because
they have defective complement regulation in the kidney (8, 9). We
have previously characterized the FH deficiency in a child who
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presented a homozygous single nucleotide substitution (CG453T
to CA453T) leading to an R127H substitution in the FH protein
(10). This patient presented undetectable complement-mediated
hemolytic activity, undetectable levels of C3 and FB, and very
low serum levels of FH (10). Furthermore, the mutant Arg127His
mutation in FH (FHR127H) is retained intracellularly and slowly
secreted to the cell culture supernatant (10). In this study, we
investigated the mechanisms by which this mutation causes defi-
ciency of this protein in the patient’s serum. Our results show that
FHR127H is retained in the endoplasmic reticulum (ER) of patient
fibroblasts, and we present evidence that chemical chaperones
may aid to stabilize the mutant protein and consequently restore
its ability to be secreted. These chaperones may therefore repre-
sent potential therapeutic agents in the treatment of FH-deficient
patients carrying this lesion or lesions with similar effects on FH
stability.
Materials and Methods
Cell culture and reagents
Primary human fibroblasts were isolated by skin biopsy as described
previously (11) and modified later (12). The Institutional Review Board
approved the project, and informed consent was obtained from the
patient’s family. Cos-7 cells were purchased from the American Tissue
Culture Collection. Primary fibroblast and Cos-7 cell cultures were
maintained in DMEM supplemented with 10% heat-inactivated FCS
(Invitrogen Life Technologies) and 100 U/ml penicillin, 100 mg/ml
streptomycin (Bio-Lab), and 2 mM L-glutamine (Invitrogen Life Tech-
nologies).
Cell culture treatments
Patient fibroblast cultures were treated with 1 and 2 mM curcumin (Sigma-
Aldrich) dissolved in DMSO or with 1 and 2 mM 4-phenylbutyric acid
(PBA; Sigma-Aldrich) dissolved in Milli-Q H2O for up to 24 h.
Expression of FH by transfected Cos-7 cells
PCR-based, site-directed mutagenesis (QuickChange II Site-Directed
Mutagenesis kit; Stratagene) was used to introduce the CA453T substitu-
tion in the FH cDNA contained within the mammalian expression vector
pIC-neo (Promega) kindly provided by Dr. Santiago de Co´rdoba from
Centro de Investigaciones Biolo´gicas, Conseio Superior de Investigaciones
Cientı´ficas, Madrid, Spain (13). The following mutagenic primers were
used (the altered bases are highlighted in bold): 59-GCTAGGTGAGA-
TTAATTACCATGAATGTGACACAGATGGATG-39 and 59-CATCCATC-
TGTGTCACATTCATGGTAATTAATCTCACCTAGC-39. Cos-7 cells (1.53
105 cells/well) were transfected with 650–750 ng pIC-Neo containing wild-
type (CG453T) or mutant (CA453T) FH cDNA, using 3 ml lipofectamine
2000 (Invitrogen Life Technologies) according to the manufacturer’s pro-
tocol. The clones were selected using DMEM containing G418 (1 mg/ml)
for 7 d, and FH production was evaluated by immunofluorescence.
Analysis of FH secretion by Western blotting
Skin fibroblasts (106 cells) from the patient and a normal control were
cultured and stimulated with 100 U/ml IFN-g (R&D Systems) for 6, 12,
24, and 48 h. This cytokine enhances the expression of FH by fibroblasts
(14). After incubation, we separated the cells and the cell culture super-
natants. The cells were suspended in 100 ml lysis buffer (PBS 1X, 10 mM
EDTA, 2mM phenylmethanesulfonylfluoride, 1% Triton X-100 and pro-
tease inhibitor mixture; GE Healthcare). After one cycle of freezing and
thawing, cell lysates were subjected to centrifugation for 5 min at 10,0003 g
and the supernatants were harvested for further analysis. The supernatants
were concentrated 10 times by lyophilization. The protein concentration of
each sample was determined using Bradford’s protein assay, and equiva-
lent amounts of protein were separated by SDS-PAGE. After transfer onto
a nitrocellulose membrane, nonspecific sites were blocked with TBS-
Tween buffer (5 mM Tris-HCl [pH 8.0], 75 mM NaCl, 0.028% Tween-
20) containing 5% nonfat dried milk, for 1 h at room temperature. The
membrane was then treated with rabbit anti-human FH Ab (1:10,000;
kindly provided by Dr. Pilar Sa´nchez, Unidad de Inmunologı´a, Hospital
Universitario La Paz, Madrid, Spain) for 2 h at room temperature. The
membrane was then incubated with an HRP-conjugated secondary Ab
(1:10,000; Sigma-Aldrich) for 1 h at room temperature. Bands were vi-
sualized with an ECL reagent (Pierce) after exposition of Hyperfilm ECL
(GE Healthcare). Western blot analysis to evaluate FH secretion by trans-
fected Cos-7 cells was carried out using goat anti-human FH (1:10,000;
Quidel) as primary Ab using the procedure described earlier.
Immunofluorescence microscopy
Human fibroblasts were stimulated with 100 U/ml IFN-g for 24 h and
prepared for confocal microscopy immunofluorescence as described pre-
viously (10). Cells were labeled with rabbit anti-human FH (kindly pro-
vided by Dr. Peter Zipfel, Department of Infection Biology, Leibniz
Institute for Natural Product Research and Infection Biology, Hans-Kno¨ll-
Institute, Jena, Germany). To determine the intracellular location of the
mutant FH protein within the patient’s fibroblasts, we also used the fol-
lowing Abs: mouse anti-calnexin (ER marker; BD Bioscience), mouse
anti–a-mannosidase (Golgi complex marker), and mouse anti-b COP (ER,
Golgi complex, and vesicles from Golgi complex marker), kindly provided
by Dr. Antonio Sesso (Faculty of Medicine, University of Sa˜o Paulo, Sa˜o
Paulo, Brazil). We also used DAPI for nuclei labeling. Anti-IgG secondary
Abs were conjugated with FITC or tetramethylrhodamine isothiocyanate
(Sigma-Aldrich). The analyses were performed using a confocal micros-
copy (ZEISS LSM 510 Meta).
Transmission electron microscopy
For electron microscopy, 53 105 human fibroblasts were cultured with 100
U/ml IFN-g for 48 h. Cells were then harvested by centrifugation at 750 3
g for 5 min and washed in PBS. The cells were fixed with 4% formalde-
hyde, 2.5% glutaraldehyde in 0.2 M sodium cacodylate buffer, pH 7.3, for
24 h at 4˚C. After fixation, the cells were centrifuged at 750 3 g for 5 min,
and the pellet was washed twice and postfixed for 2 h with 1% osmium
tetroxide and 0.8% potassium ferrocyanide in 0.2 M sodium cacodylate
buffer. The pellet was then washed and incubated with 0.5% uranyl ace-
tate, 10% sucrose solution for 24 h at 4˚C. Finally, the pellet was dehy-
drated through an increasing alcohol series (70–100%), infiltrated with
propylene oxide plus resin (v/v) for 12 h, and embedded in Spurr resin.
Ultra-thin sections were observed in a transmission electron microscopy
(JEOL 100C-XL).
FH cofactor activity assay
FH protein was purified by immunoaffinity chromatography from super-
natants of patient and control fibroblast cultures. We incubated 250 ng C3b,
100 ng FI (Complement Technology), and 100–200 ng purified FH in PBS
solution (final volume 50 ml) for 3 h at 37˚C. An aliquot of 4 3 reducing
SDS buffer (250 mM Tris-HCl 1M pH 6.8, 10% SDS, 0.5% bromophenol
blue, 50% glycerol, 7% 2-ME) was then added to the samples and heated
for 5 min at 95˚C before loading into SDS-PAGE. The FH cofactor activity
was confirmed after visualization of an ∼43-kDa band corresponding to
iC3b by Western blotting.
Results
FH secretion analysis
To determine whether cells from the deficient patient are able to
synthesize and secrete the FHR127H mutant, we stimulated skin
fibroblasts from this patient and a normal individual with IFN-g
for 6, 12, 24, and 48 h, and analyzed the cellular and secreted FH
by Western blotting. FH molecules with the expected size (150
kDa; Fig. 1A) could be detected in fibroblast cultures from both
patient and control cells. However, the patient and control cells
presented significant differences in the temporal evolution of their
FH secretion ratios. Although normal cells secrete wild-type FH in
,6 h after synthesis and do not accumulate significant amounts
intracellularly, patient fibroblasts retain the mutant protein intra-
cellularly, and the mutant FH is observed in the culture super-
natants only 48 h after IFN-g treatment (Fig. 1A). To determine
whether the observed delay in FH secretion by patient fibroblasts
is due to the FHR127H mutation itself or to some other factor in the
deficient patient cells, we transfected Cos-7 cells with pIC-neo-FH
CG453T (wild-type) and pIC-Neo FH CA453T (mutant) plasmids.
Fig. 1B shows that extracellular wild-type FH levels are always
greater than the intracellular levels, whereas the intracellular
levels of the mutant FH protein are greater than the extracellular
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levels at all times. These results confirm that the R127H mutation
does, in fact, reduce the efficiency of FH secretion by patient
fibroblasts.
FHR127H presents normal regulatory activity
Considering the low levels of mutant FHR127H in the patient serum
and the slow kinetics of FH secretion by patient fibroblasts, we
asked whether the mutant protein could carry out specific func-
tions attributed to FH in the regulation of the alternative pathway
of the complement system. To approach this question, we first
incubated patient and normal control serum with purified C3b and
FI for 3 h at 37˚C. Under these conditions, both sera cleaved C3b,
generating an ∼43-kDa band, which corresponds to one of iC3b
a9-chains (Fig. 2A). The 67-kDa band from iC3b a9-chain was not
observed probably because it comigrates with the iC3b b-chain
(70 kDa). To confirm this result, we asked whether purified mutant
FHR127H was able to cleave C3b into iC3b. We therefore obtained
wild-type and mutant FH molecules from skin fibroblast culture
supernatants or from transfected Cos-7 cell supernatants by puri-
fication using anti-FH linked immunoaffinity chromatography.
Equal amounts of purified wild-type FH or mutant FHR127H pro-
teins were incubated with commercial C3b and FI for 3 h at 37˚C.
We observed that the mutant protein was able to cleave C3b into
iC3b with efficiency equal to that of wild-type FH (Fig. 2B).
Therefore, both wild-type FH and mutant FHR127H proteins are
able to act as a cofactor of FI in the cleavage of C3b.
Intracellular localization of mutant protein FHR127H
The observed delay in secretion of the mutant FHR127H raised the
question as to in which intracellular compartment this mutant
protein is retained in the patient’s cells. To address this question,
we stimulated patient’s fibroblast cultures with IFN-g for 24 h and
then labeled with anti-FH Ab for immunofluorescence analysis.
Fibroblasts from the FH-deficient patient presented more intense
intracellular labeling than fibroblasts from the normal control (Fig.
3A). This result is consistent with the delayed secretion and in-
tracellular accumulation of mutant FHR127H observed after West-
ern blotting analysis shown in Fig. 1. Furthermore, we observed a
diffuse reticular staining of the cytoplasm especially prominent in
the perinuclear region (Fig. 3A), suggesting that mutant FHR127H
could be retained near the Golgi complex. We observed that
mutant FHR127H colocalizes with b-COP, a well-known marker
of ER and Golgi complex (Fig. 3A). These results suggest that
FHR127H is retained within these compartments.
FIGURE 1. Secretion ratio of FH by fibroblasts. (A) Human fibroblasts
were treated with IFN-g. (B) Cos-7 cells were transfected with pIC-neo-FH
CG453T (mutant) or pIC-neo-FH CA453T (wild-type). After incubation, the
cell lysates and supernatants were harvested, concentrated, and equal
amounts of protein were loaded in SDS gel, followed by Western blot
analysis using anti-human FH.
FIGURE 2. Evaluation of cofactor ac-
tivity of mutant FH. (A) Purified commer-
cial C3b and FI were incubated with 1 or
5% serum for 3 h. (B) C3b and FI were
incubated with 100 or 200 ng FH purified
from supernatant of patient’s and control’s
fibroblasts for 3 h. FH cofactor activity
was evaluated by the presence of the C3b
cleavage product (C3 a9-chain fragment,
43 kDa).
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To investigate this question further, we labeled the patient
fibroblasts with anti-FH, with anti–a-mannosidase Ab specific to
the Golgi complex, and with anti-calnexin Ab specific for the
ER. Moderate colocalization of FHR127H and anti–a-mannosidase
was observed. The greater part of FHR127H staining was observed
outside the Golgi complex, suggesting another compartment
where the mutant protein was retained in the patient cells (Fig.
3B). In double-staining experiments using anti-FH and anti-
calnexin, we observed colocalization between FH and calnexin,
confirming that the protein is retained in the ER (Fig. 3C).
We then asked whether mutant FH retention resulted in other
intracellular modifications. To address this, we used electronic
microscopy to analyze patient and control fibroblasts after treat-
ment with IFN-g for 48 h. We observed that the patient’s fibro-
blasts presented larger ER cisterns than control fibroblasts (Fig. 4).
This modification in ER structure has been associated with the
response to the accumulation of unfolded proteins during ER
stress.
Evaluation of the secretion by fibroblasts of FH patients
treated with chemical chaperones
Because the mutant FHR127H protein has regulatory activity but
may be causing ER stress, we sought to improve FH secretion by
treating the patient’s cells with drugs that facilitate protein fold-
ing. Different investigators have used chemical chaperones, such
as curcumin and PBA, to improve the secretion of unfolded pro-
teins (15–18). We therefore treated patient’s fibroblasts with in-
creasing doses of curcumin and PBA for 24 h. Both drugs
improved the in vitro secretion of mutant FHR127H by fibroblasts
after 24 h treatment even in the absence of IFN-g. Concentration–
response analysis of FH secretion in response to chemical chap-
erone treatment showed that the effect in the FH secretion was
maximal at a curcumin concentration of 2 mM and a PBA con-
centration of 2 mM (Fig. 5A). In addition, we noted that the effect
of these chaperones persists for at least 12 h posttreatment for both
drugs (Fig. 5B, 5C). However, the maximal effect was observed
within 6 h after treatment. Western blot analysis showed that the
effect of curcumin lasts longer than that of PBA because the
corresponding 150-kDa band was still intense even after 24 h.
Discussion
Complete FH deficiency (homozygous) is rare: only 23 cases in
13 different families have been reported in the literature (8, 9).
Patients with absence or dysfunction of FH are more susceptible to
bacterial infections and development of MPGN II. This latter
disease is associated with abnormalities of complement regulation
and can be observed in patients carrying homozygous or hetero-
zygous FH deficiencies. These patients exhibit mutations located
in different regions of this protein such as Cys518Arg, Cys941Tyr
(19), Arg127Leu, Cys431Ser, Cys673Ser, Cys673Tyr (8), DLys224
(20), Pro139Ser (21). All these mutations are associated with se-
cretion delay of FH.
Our laboratory characterized a case of FH deficiency in a male
child with several episodes of pneumonia. Low levels of FH (16.8
mg/ml; reference range: 225–1636 mg/ml) and undetectable levels
of C3 and FB were observed in his serum, confirming an immu-
nochemical profile compatible with FH deficiency (10) because
the loop of amplification of the alternative pathway is uncon-
trolled. The patient carries a mutation in his FH gene that results
in an R127H substitution in FH SCR2 (10). An equivalent mutation
was previously observed in two brothers carrying MPGN II, but
it was not characterized further (8).
In this study, we explored the consequences of the FHR127H
mutation on FH production by the patient cells. The results
showed that even though the patient is able to synthesize FH
protein, most of the mutant protein is retained intracellularly in the
patient’s fibroblasts. We observed a similar secretion delay when
in transfected Cos-7 cells expressing the mutant protein. There-
fore, this impaired FH secretion is not caused by an intrinsic
defect in the patient’s fibroblasts, and it is a consequence of the
R127H substitution in the FH molecule.
FHR127H is retained in intracellular compartments of the se-
cretory pathway, which includes Golgi complex and ER as ob-
served when patient’s fibroblasts were labeled with anti–b-COP
and anti-FH. Apparently, mutant FH is retained mainly in the ER
because only a slight colocalization between a-mannosidase and
mutant FH was observed in the patient’s fibroblasts. The relative
importance of the ER compartment for the retention of this FH
mutant protein was confirmed after labeling patient’s cells with
anti-calnexin and anti-FH. These results together suggest two
FIGURE 3. Intracellular localization of mutant FH in fibroblasts treated
with IFN-g, by immunofluorescence microscopy. The cells were fixed and
labeled with Ab against specific proteins. Green represents anti–b-COP
(A), anti–a-mannosidase (B), or anti-calnexin (C); red represents FH; blue
represents DAPI (nuclei); yellow represents merge. All images were ob-
tained with a plan-apochromat 633/1.4 oil differential interference con-
trast objective.
FIGURE 4. ER integrity in fibroblast’s culture from patient and control.
Black arrow indicates the ER in fibroblasts treated with IFN-g for 48 h.
Original magnification 35000 (left panels), 310,000 (right panels).
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possibilities: 1) colocalization observed in the Golgi complex is
caused by the accumulation of mutant protein molecules that have
escaped from the ER quality-control system and are transported to
a region known as the intermediate compartment of the ER–Golgi
complex. In this case, the unfolded protein cannot be released into
the Golgi complex and eventually returns to the ER, where it is
refolded or degraded (22); and 2) considering that the patient can
secrete low levels of FH, colocalization could be explained by the
presence of proteins in the process of being secreted.
A large fraction of the mutant FH protein is retained in the ER,
which may cause an abnormal accumulation of this molecule and
provoke enlargement of ER cisterns after 48 h treatment with IFN-g.
This event is characteristic of protein retention and causes ER
stress. Enlarged ER cisterns have been observed by other groups:
Truettner et al. (23) induced brain ischemia in rats and observed
the accumulation of unfolded and aggregated proteins in the cy-
toplasm, mitochondria, and ER. In another study, protein accu-
mulation and ER stress response were observed in patients with
p31 deficiency, a protein implicated in the ER organization (24).
The association between FH deficiency and protein retention at
the ER has been reported previously. Ault et al. (19) described an
FH-deficient patient who developed MPGN II. This patient was
able to synthesize FH protein, but it was retained in the ER. FH in
this patient had two substitutions (Cys518Arg and Cys914Tyr) that
disrupt disulfide bonds essential for the formation of “sushi”
domains SCR9 and SCR16 (19, 25). However, the functionality of
this protein was not tested. These substitutions are chemically
more drastic than the R127H substitution, which exchanges one
basic amino acid for another in our patient. This could explain, in
part, the low levels of serum FH.
Three high-resolution structures of human FH fragments con-
taining SCR2 have been deposited in the Protein Data Bank (PDB):
the NMR solution structures of SCR 1–2 and SCR 2–3 (PDB ID:
2RLP and 2RLQ, respectively) (26), and the crystal structure of
SCR 1–4 in complex with complement fragment C3b (PDB ID:
2WII) (27). In the crystal structure, the Arg127 side chain projects
from the internal face of a three-stranded antiparallel b-sheet to-
ward the opposite surface of the SCR2 so that the aliphatic por-
tion of the side chain is completely buried, whereas the guanidino
group is solvent exposed (Fig. 6). The ensemble of solution
structures shows that the burial of the guanidino group can vary
from highly solvent exposed to almost completely buried (26).
This suggests that SCR2 structure may be sufficiently flexible to
accommodate the sterically different histidine side chain in the
mutant protein without compromising its topology and regulatory
functionality. The substitution may, however, affect the kinetics
of protein folding leading to its retention the ER (15–18).
Although the R127H mutation is responsible for the FH secretion
delay, we demonstrated that the mutant protein is able to regulate
the alternative pathway of the complement system. Because the
mutant protein is functional and the cells are able to secrete a
small fraction of the FH produced, albeit at a lower rate, we de-
cided to try to improve FH secretion using drugs required for
protein folding. Chaperones and folding enzymes act to avoid
FIGURE 5. Effect of curcumin and PBA treatments
on FH secretion by patient’s fibroblasts. (A) Patient’s
fibroblasts were treated with 1 and 2 mM PBA or 1 and
2 mM curcumin (Cur) for 24 h. (B) Patient’s fibroblasts
were treated with 2 mM curcumin or 2 mM PBA for
3 up to 24 h. Cell lysates and supernatants were sub-
jected to Western blotting analysis with anti-FH and
HRP-conjugated secondary Ab, and the relative den-
sitometry analysis (C) was performed using the soft-
ware ImageJ and expressed in arbitrary units. The
possibility that DMSO (used to dissolve curcumin)
could be responsible for the observed increase in the
FH secretion by patient’s fibroblasts treated with cur-
cumin was discarded because the effect was curcumin
dose dependent.
FIGURE 6. Model of the FH SCR2 domain highlighting residue Arg127
(blue stick model). The exposed surface of the Arg127 guanidino group is
shown as a semitransparent blue surface. b-Strand residues are shown in
red, and random coil residues are shown in green. The model was derived
from FH residues 83–143 of the crystal structure of the C3b–FH complex
(PDB ID: 2wII) (27). The figure was produced using the Pymol molecular
graphics software.
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protein aggregation and recover misfolded proteins. Although
most chaperones studied to date are proteins, chemical chaperones
are small molecules that exhibit similar effects within the cell. For
example, pharmacological treatment with curcumin and PBA has
been explored by several groups to release unfolded proteins and
diminish the ER damage (15–18). Chemical chaperones may
therefore be a promise to treat certain diseases associated with
protein misfolding. When we treated cultures of patient’s fibro-
blasts with curcumin or PBA, we observed that both drugs ac-
celerate the secretion ratio of the mutant protein in fibroblast
cultures, and that this beneficial effect persisted for at least 6 h.
The effectiveness of chemical chaperones depends on the chemical
nature of the mutation and its structural consequences in the target
protein (15). In the case of frameshift mutations, substitutions of
specific amino acids (such as Cys, Tyr, and Pro) or amino acids with
important structural functions, these drugs could be of limited
benefit (15). Chemical chaperones are good candidates to exper-
imentally improve the secretion of FH in deficient patients
caused by mutations where relatively mild structural perturba-
tions do not compromise protein activity, but rather reduce the
secretion ratio of this important regulatory protein of the comple-
ment alternative pathway.
Although both curcumin and PBA are able to increase extra-
cellular levels of FH in vitro, curcumin was shown to be more
effective because its effects last for a longer period of time than that
of PBA. Therefore, it would be the best choice for future clinical
trials because it is found in several natural food products and used
as dietary supplement in some countries (28–31). Furthermore, the
maximum nontoxic dose of curcuminoids in humans (12 g/d) is
much higher than the dose used in oral treatment (2–8 g/d) (29, 30,
32). However, curcumin consumption can produce adverse effects
such as headaches, stomach ache, rashes, and diarrhea depending
on the patient’s sensitivity to the drug (29, 30, 32).
Curcumin is able to decrease the secretion of proinflammatory
cytokines such as IL-1b and IL-6 in PBMCs of patients with
chronic kidney disease (31). Thus, curcumin could act to decrease
inflammation triggered by complement activated fragments, re-
ducing tissue damage in deficient patients with delay of FH se-
cretion. Treatment with curcumin could increase the levels of
serum FH in those cases in which the deficiency is caused by
defects in protein folding. Increased FH levels would restore
regulation of the alternative pathway of complement system and
consequently reduce the incidence of infections, besides acting to
delay disease progression in MPGN II. Thus, the use of curcumin
could be tested as an alternative treatment to improve FH-deficient
patients’ survival carrying the FHR127H mutation (10) and related
mutations such as FHR127L reported by Dragon-Durey et al. (8).
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